TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Purified n-3 Fatty Acids on Serum Fibrosis Markers and Cardiovascular Risk Markers in a Randomized Placebo Controlled Trial in Patients With Non Alcoholic Fatty Liver Disease
Brief Summary: Non alcoholic fatty liver disease (NAFLD) imposes a high and increasing burden on the NHS, yet there is presently no licensed treatment or validated approach to management. NAFLD predisposes to increased risk of type 2 diabetes, increased risk of cardiovascular disease and may progress to chronic irreversible liver disease.

In NAFLD patients, the investigators will test the hypothesis that treatment with long chain n-3 fatty acid supplementation for 18 months favourably influences bio-markers for NAFLD and risk factors for cardiovascular disease and type 2 diabetes.


Options:
A: Intervention Type: DRUG; Name: Epanova™ (Omega-3 Free Fatty Acids); Assigned to Arm(s): N/A
B: Arm Label: Vitamin D + fish oil; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: vitamin D3, Drug: omega-3 fatty acids (fish oil) | Arm Label: Vitamin D + fish oil placebo; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: vitamin D3, Dietary Supplement: Fish oil placebo | Arm Label: Vitamin D placebo + fish oil; Type: ACTIVE_COMPARATOR; Interventions: Drug: omega-3 fatty acids (fish oil), Dietary Supplement: Vitamin D3 placebo | Arm Label: Vitamin D placebo + fish oil placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Vitamin D3 placebo, Dietary Supplement: Fish oil placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: vitamin D3; Assigned to Arm(s): Vitamin D + fish oil, Vitamin D + fish oil placebo | Intervention Type: DRUG; Name: omega-3 fatty acids (fish oil); Assigned to Arm(s): Vitamin D + fish oil, Vitamin D placebo + fish oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3 placebo; Assigned to Arm(s): Vitamin D placebo + fish oil, Vitamin D placebo + fish oil placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Fish oil placebo; Assigned to Arm(s): Vitamin D + fish oil placebo, Vitamin D placebo + fish oil placebo
C: Intervention Type: DRUG; Name: Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM); Assigned to Arm(s): N/A
D: Arm Label: Omega 3 fatty acid (fish oil); Type: ACTIVE_COMPARATOR; Interventions: Drug: OMACOR | Arm Label: dummy pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo oral capsule | Intervention Type: DRUG; Name: OMACOR; Assigned to Arm(s): Omega 3 fatty acid (fish oil) | Intervention Type: DRUG; Name: Placebo oral capsule; Assigned to Arm(s): dummy pill

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Purified n-3 Fatty Acids on Serum Fibrosis Markers and Cardiovascular Risk Markers in a Randomized Placebo Controlled Trial in Patients With Non Alcoholic Fatty Liver Disease
Brief Summary: Non alcoholic fatty liver disease (NAFLD) imposes a high and increasing burden on the NHS, yet there is presently no licensed treatment or validated approach to management. NAFLD predisposes to increased risk of type 2 diabetes, increased risk of cardiovascular disease and may progress to chronic irreversible liver disease.

In NAFLD patients, the investigators will test the hypothesis that treatment with long chain n-3 fatty acid supplementation for 18 months favourably influences bio-markers for NAFLD and risk factors for cardiovascular disease and type 2 diabetes.


Options:
A: Arm Label: N-3 PUFA; Type: EXPERIMENTAL; Interventions: Drug: N-3 Polyunsaturated Fatty Acids | Arm Label: Olive oil; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo: Olive oil | Intervention Type: DRUG; Name: N-3 Polyunsaturated Fatty Acids; Assigned to Arm(s): N-3 PUFA | Intervention Type: DRUG; Name: Placebo: Olive oil; Assigned to Arm(s): Olive oil
B: Arm Label: Omega 3 fatty acid (fish oil); Type: ACTIVE_COMPARATOR; Interventions: Drug: OMACOR | Arm Label: dummy pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo oral capsule | Intervention Type: DRUG; Name: OMACOR; Assigned to Arm(s): Omega 3 fatty acid (fish oil) | Intervention Type: DRUG; Name: Placebo oral capsule; Assigned to Arm(s): dummy pill
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Multi-nutrient supplement; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multi-nutrient supplement | Arm Label: Placebo + Behavioral Activation; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Activation, Other: Placebo | Arm Label: Multi-nutrient + Behavioral Activation; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multi-nutrient supplement, Behavioral: Behavioral Activation | Intervention Type: DIETARY_SUPPLEMENT; Name: Multi-nutrient supplement; Assigned to Arm(s): Multi-nutrient + Behavioral Activation, Multi-nutrient supplement | Intervention Type: BEHAVIORAL; Name: Behavioral Activation; Assigned to Arm(s): Multi-nutrient + Behavioral Activation, Placebo + Behavioral Activation | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo, Placebo + Behavioral Activation
D: Intervention Type: PROCEDURE; Name: Supplementation with fish oil versus placebo; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Parent-Implemented Intervention for Toddlers With Autism Spectrum (The ESI Study)
Brief Summary: This study will compare the effectiveness of two parent-based programs for helping young children at risk of autism.


Options:
A: Arm Label: ESI--Individual PII First Condition; Type: EXPERIMENTAL; Interventions: Behavioral: Early Social Interaction Project- PII, Behavioral: Early Social Interaction Project- IES | Arm Label: ESI--Group IES First Condition; Type: EXPERIMENTAL; Interventions: Behavioral: Early Social Interaction Project- PII, Behavioral: Early Social Interaction Project- IES | Intervention Type: BEHAVIORAL; Name: Early Social Interaction Project- PII; Assigned to Arm(s): ESI--Group IES First Condition, ESI--Individual PII First Condition | Intervention Type: BEHAVIORAL; Name: Early Social Interaction Project- IES; Assigned to Arm(s): ESI--Group IES First Condition, ESI--Individual PII First Condition
B: Arm Label: Caregiver Education Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Caregiver-Education Intervention | Arm Label: Caregiver-Mediated Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Caregiver-Mediated Intervention | Intervention Type: BEHAVIORAL; Name: Caregiver-Mediated Intervention; Assigned to Arm(s): Caregiver-Mediated Intervention | Intervention Type: BEHAVIORAL; Name: Caregiver-Education Intervention; Assigned to Arm(s): Caregiver Education Intervention
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Early intervention blending several tx approaches, w/ focus | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Early intervention blending several treatment approaches | Intervention Type: BEHAVIORAL; Name: Early intervention blending several tx approaches, w/ focus; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Early intervention blending several treatment approaches; Assigned to Arm(s): 2
D: Arm Label: JAE-EMT; Type: EXPERIMENTAL; Interventions: Behavioral: JAE Intervention | Arm Label: JAE-AAC; Type: EXPERIMENTAL; Interventions: Behavioral: JAE Intervention | Intervention Type: BEHAVIORAL; Name: JAE Intervention; Assigned to Arm(s): JAE-AAC, JAE-EMT

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The AZIthromycin in Severe ASThma (AZISAST) Study: a Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Efficacy, Safety and Cost-effectiveness of Azithromycin as add-on Therapy in Adult Subjects With Severe Persistent Asthma, Who Remain Inadequately Controlled Despite GINA (2006) Step 4 or 5 Therapy
Brief Summary: The purpose of this study is to evaluate the efficacy, safety and cost-effectiveness of azithromycin as add-on therapy in adult subjects with severe persistent asthma, who remain inadequately controlled despite GINA (2006) step 4 or 5 therapy.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Avelox (Moxifloxacin, BAY12-8039) | Arm Label: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Avelox (Moxifloxacin, BAY12-8039); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 2
B: Arm Label: Arm I; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Carboplatin | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel, Drug: Carboplatin, Drug: Gemcitabine Hydrochloride | Arm Label: Arm III; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel, Drug: Carboplatin, Drug: Pegylated Liposomal Doxorubicin Hydrochloride | Arm Label: Arm IV; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel, Drug: Carboplatin, Drug: Topotecan Hydrochloride | Arm Label: Arm V; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel, Drug: Carboplatin, Drug: Gemcitabine Hydrochloride, Procedure: Therapeutic Conventional Surgery | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm I, Arm II, Arm III, Arm IV, Arm V | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm I, Arm II, Arm III, Arm IV, Arm V | Intervention Type: DRUG; Name: Gemcitabine Hydrochloride; Assigned to Arm(s): Arm II, Arm V | Intervention Type: DRUG; Name: Pegylated Liposomal Doxorubicin Hydrochloride; Assigned to Arm(s): Arm III | Intervention Type: DRUG; Name: Topotecan Hydrochloride; Assigned to Arm(s): Arm IV | Intervention Type: PROCEDURE; Name: Therapeutic Conventional Surgery; Assigned to Arm(s): Arm V
C: Arm Label: Azithromycin; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin 250 mg | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin 250 mg; Assigned to Arm(s): Azithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
D: Arm Label: Azithromycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The AZIthromycin in Severe ASThma (AZISAST) Study: a Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Efficacy, Safety and Cost-effectiveness of Azithromycin as add-on Therapy in Adult Subjects With Severe Persistent Asthma, Who Remain Inadequately Controlled Despite GINA (2006) Step 4 or 5 Therapy
Brief Summary: The purpose of this study is to evaluate the efficacy, safety and cost-effectiveness of azithromycin as add-on therapy in adult subjects with severe persistent asthma, who remain inadequately controlled despite GINA (2006) step 4 or 5 therapy.


Options:
A: Arm Label: Azithromycin; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin 250 mg | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin 250 mg; Assigned to Arm(s): Azithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
B: Arm Label: End User Iterative Testing - CampAir; Type: OTHER; Interventions: Behavioral: CampAir | Intervention Type: BEHAVIORAL; Name: CampAir; Assigned to Arm(s): End User Iterative Testing - CampAir
C: Arm Label: Reference; Type: OTHER; Interventions: Behavioral: Marketed experience application on adherence | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Marketed experience application on adherence | Intervention Type: BEHAVIORAL; Name: Marketed experience application on adherence; Assigned to Arm(s): Intervention, Reference
D: Arm Label: BreatheSmart System; Type: EXPERIMENTAL; Interventions: Device: BreatheSmart System | Arm Label: Standard of Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard of Care | Intervention Type: DEVICE; Name: BreatheSmart System; Assigned to Arm(s): BreatheSmart System | Intervention Type: OTHER; Name: Standard of Care; Assigned to Arm(s): Standard of Care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The AZIthromycin in Severe ASThma (AZISAST) Study: a Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Efficacy, Safety and Cost-effectiveness of Azithromycin as add-on Therapy in Adult Subjects With Severe Persistent Asthma, Who Remain Inadequately Controlled Despite GINA (2006) Step 4 or 5 Therapy
Brief Summary: The purpose of this study is to evaluate the efficacy, safety and cost-effectiveness of azithromycin as add-on therapy in adult subjects with severe persistent asthma, who remain inadequately controlled despite GINA (2006) step 4 or 5 therapy.


Options:
A: Arm Label: Azithomycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithomycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Azithromycin; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin 250 mg | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin 250 mg; Assigned to Arm(s): Azithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
C: Arm Label: Azithromycin; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Biannual mass oral azithromycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Biannual mass oral placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Biannual mass oral azithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Biannual mass oral placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Music to Reduce Pain and Anxiety in the Pediatric Emergency Department: a Randomized Controlled Trial of Children 3-6 Years Undergoing Intravenous Placement
Brief Summary: Many medical procedures aimed at helping children can cause them pain and distress. If children experience certain levels of pain or distress, it can have long lasting negative effects. The emergency department can be a particularly stressful place for children and their parents. There are also many procedures that children may have in the emergency department that can cause pain and distress. These include procedures such as needle pokes, stitches, or setting a broken bone. Two common methods of managing a child's pain in the emergency department are drugs and distraction. Drugs are not always practical and may come with unwanted side effects. Distraction is often used formally or informally and by parents or the health professionals. One form of distraction involves listening to music. This can lower the child's pain and distress by moving their attention from the painful stimulus, for example a needle poke, to a more pleasant sensation such as familiar children's songs. This study will test whether music is useful to help lower pain and distress for young children (ages 3 to 6 years) who are visiting an emergency department and need an intravenous line. Music is safe and pleasant for children. The results from this study could be important for many children receiving medical care.


Options:
A: Arm Label: humanoid robot distration; Type: N/A; Interventions: N/A | Arm Label: control; Type: N/A; Interventions: N/A
B: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: info group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: info | Arm Label: smartphone group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: smartphone | Arm Label: smartphone and info group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: info, Behavioral: smartphone | Intervention Type: BEHAVIORAL; Name: info; Assigned to Arm(s): info group, smartphone and info group | Intervention Type: BEHAVIORAL; Name: smartphone; Assigned to Arm(s): smartphone and info group, smartphone group
C: Arm Label: Hypnovel® (midazolam); Type: ACTIVE_COMPARATOR; Interventions: Drug: Midazolam oral intake | Arm Label: Electronic tab; Type: EXPERIMENTAL; Interventions: Procedure: electronic tab | Intervention Type: PROCEDURE; Name: electronic tab; Assigned to Arm(s): Electronic tab | Intervention Type: DRUG; Name: Midazolam oral intake; Assigned to Arm(s): Hypnovel® (midazolam)
D: Arm Label: music; Type: EXPERIMENTAL; Interventions: Behavioral: music | Arm Label: Standard care; Type: OTHER; Interventions: Behavioral: music | Intervention Type: BEHAVIORAL; Name: music; Assigned to Arm(s): Standard care, music

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: To Verify the Efficacy of Z-338 in Subjects With Functional Dyspepsia, Focusing on the Assessment of Subjective Symptoms
Brief Summary: The purpose of this study is to verify the superior efficacy of Z-338 to placebo in subjects with Functional Dyspepsia, focusing on the assessment of subjective symptoms.


Options:
A: Arm Label: Z-338; Type: EXPERIMENTAL; Interventions: Drug: Z-338 | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Z-338; Assigned to Arm(s): Z-338 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
B: Intervention Type: DRUG; Name: Esomeprazole; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Cinitapride | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: domperidone | Intervention Type: DRUG; Name: Cinitapride; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: domperidone; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: Itopride (drug); Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Fixation Using Alternative Implants for the Treatment of Hip Fractures: A Multi-Centre Randomized Trial Comparing Sliding Hip Screws and Cancellous Screws on Revision Surgery Rates and Quality of Life in the Treatment of Femoral Neck Fractures
Brief Summary: Each year, hip fracture, an injury that can impair independence and quality of life, occurs in about 280,000 Americans and 36,000 Canadians. The annual healthcare costs associated with this injury are expected to soon reach $9.8 billion in the United States and $650 million in Canada. It is important to have in place optimal practice guidelines for the surgical handling of this injury. One type of hip fracture, called a femoral neck fracture, is often treated with a surgical procedure called internal fixation. When performing internal fixation, most orthopaedic surgeons favor using multiple small diameter screws over using a single large diameter screw with a sliding plate. However, use of the sliding hip screw might in fact result in fewer complications after surgery and reduce the need for a second surgery, called a revision surgery. This study will compare the two different surgical procedures to determine which one results in better outcomes after surgery.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: Total hip arthroplasty | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Hemi-arthroplasty | Intervention Type: DEVICE; Name: Total hip arthroplasty; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: Hemi-arthroplasty; Assigned to Arm(s): 2
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Device: Dual mobility cup | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard cup | Intervention Type: DEVICE; Name: Dual mobility cup; Assigned to Arm(s): Intervention | Intervention Type: DEVICE; Name: Standard cup; Assigned to Arm(s): Control
C: Arm Label: Single Sliding Hip Screw; Type: EXPERIMENTAL; Interventions: Device: Open reduction internal fixation (ORIF) with single sliding hip screw | Arm Label: Multiple Cancellous Screws; Type: EXPERIMENTAL; Interventions: Device: ORIF with multiple cancellous screws | Intervention Type: DEVICE; Name: Open reduction internal fixation (ORIF) with single sliding hip screw; Assigned to Arm(s): Single Sliding Hip Screw | Intervention Type: DEVICE; Name: ORIF with multiple cancellous screws; Assigned to Arm(s): Multiple Cancellous Screws
D: Arm Label: Arthroplasty; Type: EXPERIMENTAL; Interventions: Device: Arthroplasty | Arm Label: Internal Fixation; Type: ACTIVE_COMPARATOR; Interventions: Device: Internal Fixation | Intervention Type: DEVICE; Name: Arthroplasty; Assigned to Arm(s): Arthroplasty | Intervention Type: DEVICE; Name: Internal Fixation; Assigned to Arm(s): Internal Fixation

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Autologous Bone Marrow Stem Cells in Middle Cerebral Artery Acute Stroke Treatment
Brief Summary: The aim of the study is to determine the safety and efficacy on an autologous CD34+ subset bone marrow stem cell infusion into the middle cerebral artery in patients who have suffered acute middle cerebral artery stroke.


Options:
A: Arm Label: Stem Cells; Type: EXPERIMENTAL; Interventions: Biological: Autologous bone marrow mononuclear cell transplantation | Intervention Type: BIOLOGICAL; Name: Autologous bone marrow mononuclear cell transplantation; Assigned to Arm(s): Stem Cells
B: Arm Label: Autologous bone marrow stem cell; Type: EXPERIMENTAL; Interventions: Biological: Autologous bone marrow stem cell | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Autologous bone marrow stem cell; Assigned to Arm(s): Autologous bone marrow stem cell
C: Arm Label: Mesenchymal stem cell treatment; Type: EXPERIMENTAL; Interventions: Other: Mesenchymal stem cell | Arm Label: Standard treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Mesenchymal stem cell; Assigned to Arm(s): Mesenchymal stem cell treatment
D: Arm Label: bone marrow stem cells; Type: OTHER; Interventions: Procedure: Infusion on autologous CD34+ stem cells into middle cerebral artery | Intervention Type: PROCEDURE; Name: Infusion on autologous CD34+ stem cells into middle cerebral artery; Assigned to Arm(s): bone marrow stem cells

Answer: D